Avacta receives ODD from US Food and Drug Administration for AVA6000 to treat soft tissue sarcoma
5 September 2022 -

Oncology drug company Avacta Group plc (AIM: AVCT) announced on Monday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AVA6000, the company's lead pre|CISION drug candidate, AVA6000.

AVA6000 is a treatment for soft tissue sarcoma and is a form of the generic chemotherapy doxorubicin that has been modified using the pre|CISION technology so that it is activated predominantly in the tumour with the aim of sparing healthy tissue from exposure and improving the safety, tolerability and efficacy of the drug.

Avacta said that doxorubicin is widely used as part of the standard of care in several cancer types and has a market size that is expected to grow to USD1.38bn by 2024.

The company added that it has an ongoing Phase 1 clinical trial to assess the safety and pharmacokinetics of AVA6000 which has potential as a treatment for patients with a range of cancer types such as soft tissue sarcoma, a rare mesenchymal malignancy.